Piperazin-2-one → HCID 58614776, compound
Reaction equation
Cl[C:2]1[CH:23]=[CH:22][C:5]([C:6]([NH:8][C:9]2[CH:14]=[CH:13][C:12]([Cl:15])=[C:11]([C:16]3[CH:21]=[CH:20][CH:19]=[CH:18][N:17]=3)[CH:10]=2)=[O:7])=[C:4]([CH3:24])[N:3]=1.[NH:25]1[CH2:30][CH2:29][NH:28][CH2:27][C:26]1=[O:31]>C(O)CCC>[Cl:15][C:12]1[CH:13]=[CH:14][C:9]([NH:8][C:6](=[O:7])[C:5]2[CH:22]=[CH:23][C:2]([N:28]3[CH2:29][CH2:30][NH:25][C:26](=[O:31])[CH2:27]3)=[N:3][C:4]=2[CH3:24])=[CH:10][C:11]=1[C:16]1[CH:21]=[CH:20][CH:19]=[CH:18][N:17]=1Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
Procedure F was performed using 100 mg of 6-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-2-methylnicotinamide and 84 mg of piperazine-2-one in 1 mL of BuOH. Purified by reverse phase HPLC to yield N-(4-chloro-3-(pyridin-2-yl)phenyl)-2-methyl-6-(3-oxopiperazin-1-yl)nicotinamide.
Workup
- customPurified by reverse phase HPLC
Sources & evidence
- ORD record
- ord-a1cf3e3dfcf4484689d14f0d9fbb0d87
- Source dataset
- uspto-grants-2016_04
- Patent number
- US09321761B2
Reaction notes
Loading…